HOME >> BIOLOGY >> NEWS
NIAID unveils bioterrorism research agenda

The National Institute of Allergy and Infectious Diseases (NIAID) today released the NIAID Counter-Bioterrorism Research Agenda for CDC Category A Agents, a document describing the Institute's accelerated research plan for the most threatening agents of bioterrorism. The agenda outlines the research NIAID will undertake to help protect civilian populations from diseases such as smallpox, anthrax and plague should they be unleashed intentionally by those who wish to do harm.

The comprehensive plan includes short-, intermediate- and long-term research goals and describes specifically how bioterrorism countermeasures will be developed for each microbe. The document also contains a copy of the Strategic Plan for Counter-Bioterrorism Research of the NIAID, which provides a general overview of the Institute's broad plans for attacking the full range of potential bioterrorism pathogens.

"Research is a vital element of bioterrorism defense," says HHS Secretary Tommy G. Thompson. "The NIAID Counter-Bioterrorism Research Agenda describes the highest priorities of an accelerated program to expand research on bioterrorism agents and to quickly develop new diagnostics, drugs and vaccines to protect the public."

The Research Agenda was developed by NIAID scientists and reviewed by an outside panel of experts from academia, industry and government in early February. The plan focuses on the Category A diseases as described by the Centers for Disease Control and Prevention (CDC): anthrax, smallpox, plague, tularemia, viral hemorrhagic fevers and botulism. Those diseases cause high death rates or serious illness, are relatively easy to spread, could cause public panic or require special steps for public health preparedness. NIAID plans to develop research plans for CDC Category B and C agents in the near future.

As the National Institutes of Health's lead institute on immunology and infectious diseases research, NIAID has made many key contribu
'"/>

Contact: Sam Perdue
sp189u@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
14-Mar-2002


Page: 1 2 3 4

Related biology news :

1. TIGR and NIAID sign $65 million microbial sequencing contract
2. NIAID takes next genome step
3. NIAID awards grant to rapidly sequence the malaria mosquito genome
4. NIAID launches major step in trial of experimental shingles vaccine
5. NIAID-Supported Scientists Discover Origin Of HIV-1
6. NIAID Scientists Discover HIV Disease-Slowing Mutation
7. NIAID Doctor Successfully Treats Longest Case Of Malaria Infection On Record
8. Pacific Northwest team unveils largest virus proteome to date
9. Pacific Northwest National Lab unveils most complete human blood-plasma proteome map to date
10. Department of Energys Office of Science unveils 20-year vision for the future of basic research
11. Ancient DNA analysis unveils mystery of historys most horribly deformed man -- The Elephant Man

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/12/2019)... SASKATOON, Canada (PRWEB) , ... February 12, 2019 ... ... immediately it will begin operating under its new name, KEYLEAF. The company ... more of its own plant-based extracts and ingredients as finished products under the ...
(Date:2/2/2019)... ... January 31, 2019 , ... ... geared toward clinical operations executives and focusing on all facets of clinical trial ... project management, portfolio management, resource management, patient engagement, and more. , “We ...
(Date:1/25/2019)... ... January 24, 2019 , ... ... PhD, Assistant Professor of Microbiology at the Jackson Laboratory (JAX), to its Scientific ... world, Dr. Oh will bring to uBiome expertise in skin microbial interactions and ...
Breaking Biology News(10 mins):
(Date:2/12/2019)... ... February 12, 2019 , ... ... has finalized a deal to extend their use of Medrio, the leading provider ... 2023. The CRO has been a regular Medrio customer for over nine years, ...
(Date:2/2/2019)... ... , ... Signature Matrix and Signature Cord are the culmination ... cell research expert and Amazon best-selling author, Neil Riordan, PA, PhD, and his ... allograft that originates from the same tissue used to manufacture the purified, expanded ...
(Date:1/30/2019)... ... January 29, 2019 , ... ... Lifecycle since 2016. In his position as Director of Sales and Marketing, Mr. ... services supplier across multiple industries the company supports. During this time, Mr. Schieving ...
(Date:1/30/2019)... ... January 30, 2019 , ... The Society for Laboratory ... to discuss best practices for laboratory automation and screening. This year the conference ... year’s conference, Visikol will be at booth #345 and throughout the conference will ...
Breaking Biology Technology:
Cached News: